Electromed Financials
ELMD Stock | USD 29.79 1.72 6.13% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Debt Equity Ratio | 0.0549 | 0.0578 |
|
| |||||
Current Ratio | 4.13 | 5.7539 |
|
|
Investors should never underestimate Electromed's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Electromed's cash flow, debt, and profitability to make informed and accurate decisions about investing in Electromed.
Net Income |
|
Electromed | Select Account or Indicator |
Understanding current and past Electromed Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Electromed's financial statements are interrelated, with each one affecting the others. For example, an increase in Electromed's assets may result in an increase in income on the income statement.
Please note, the presentation of Electromed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Electromed's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Electromed's management manipulating its earnings.
Electromed Stock Summary
Electromed competes with Neuropace, Orthopediatrics Corp, SurModics, Paragon 28, and LivaNova PLC. Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation therapy in pulmonary care for patients of various ages in the United States and internationally. The company was incorporated in 1992 and is headquartered in New Prague, Minnesota. Electromed operates under Medical Devices classification in the United States and is traded on AMEX Exchange. It employs 156 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NYSE MKT Exchange |
ISIN | US2854091087 |
CUSIP | 285409108 |
Location | Minnesota; U.S.A |
Business Address | 500 Sixth Avenue |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | smartvest.com |
Phone | 952 758 9299 |
Currency | USD - US Dollar |
Electromed Key Financial Ratios
Return On Equity | 0.13 | ||||
Profit Margin | 0.09 % | ||||
Operating Margin | 0.16 % | ||||
Price To Sales | 4.34 X | ||||
Revenue | 54.72 M |
Electromed Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 33.2M | 37.1M | 41.4M | 45.8M | 52.2M | 28.3M | |
Other Current Liab | 2.4M | 3.7M | 5.8M | 6.3M | 6.4M | 6.7M | |
Net Debt | (10.4M) | (11.8M) | (8.1M) | (7.2M) | (16.1M) | (15.3M) | |
Retained Earnings | 13.7M | 14.9M | 15.8M | 18.8M | 23.7M | 24.9M | |
Accounts Payable | 555.5K | 685K | 1.3M | 1.4M | 1.0M | 814.3K | |
Cash | 10.5M | 11.9M | 8.2M | 7.4M | 16.1M | 16.9M | |
Other Assets | 755K | 1.1M | 1.5M | 1.6M | 1.0 | 0.95 | |
Net Receivables | 14.1M | 17.4M | 21.3M | 24.6M | 24.1M | 13.3M | |
Inventory | 3.1M | 2.1M | 3.2M | 4.2M | 3.7M | 2.6M | |
Other Current Assets | 353.3K | 276K | 1.9M | 1.6M | 329.0K | 312.6K | |
Total Liab | 3.0M | 4.7M | 7.2M | 8.1M | 7.7M | 5.6M | |
Total Current Assets | 28.0M | 31.7M | 34.5M | 37.8M | 44.2M | 22.7M | |
Short Term Debt | 30.3K | 72.3K | 33K | 80K | 72K | 68.4K | |
Intangible Assets | 598.4K | 663K | 599K | 605K | 657K | 624.2K | |
Common Stock | 84.1K | 85.7K | 85K | 86K | 87K | 87.1K | |
Net Tangible Assets | 29.7M | 31.8M | 33.6M | 37.1M | 42.6M | 24.2M | |
Capital Surpluse | 16.5M | 17.4M | 18.3M | 18.8M | 21.6M | 16.7M | |
Net Invested Capital | 30.2M | 32.4M | 34.2M | 37.7M | 44.5M | 34.1M |
Electromed Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 120.7K | 27K | 25K | 78K | 89.7K | 85.2K | |
Total Revenue | 32.5M | 35.8M | 41.7M | 48.1M | 54.7M | 28.9M | |
Gross Profit | 25.2M | 27.3M | 31.4M | 36.5M | 41.7M | 21.8M | |
Operating Income | 5.1M | 3.1M | 3.0M | 4.0M | 6.6M | 6.9M | |
Ebit | 5.1M | 3.1M | 3.0M | 4.0M | 6.6M | 6.9M | |
Research Development | 1.0M | 1.7M | 1.4M | 916K | 656K | 781.7K | |
Ebitda | 5.9M | 3.8M | 3.6M | 4.6M | 7.4M | 7.8M | |
Cost Of Revenue | 7.3M | 8.5M | 10.2M | 11.5M | 13.0M | 7.1M | |
Income Before Tax | 5.2M | 3.2M | 3.0M | 4.1M | 7.0M | 7.4M | |
Net Income | 4.2M | 2.4M | 2.3M | 3.2M | 5.2M | 5.4M | |
Income Tax Expense | 1.1M | 805K | 692K | 920K | 1.9M | 2.0M | |
Tax Provision | 1.1M | 805K | 692K | 920K | 1.9M | 1.1M | |
Net Interest Income | 120.7K | 39K | 25K | 78K | 455K | 477.8K |
Electromed Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (449.3K) | 971K | (1.1M) | (1.0M) | 459K | 482.0K | |
Change In Cash | 2.7M | 1.4M | (3.7M) | (781K) | 8.7M | 9.1M | |
Free Cash Flow | 3.2M | 2.6M | (2.2M) | (401K) | 8.7M | 9.1M | |
Depreciation | 738.2K | 610K | 628K | 613K | 841K | 684.7K | |
Other Non Cash Items | 2.6K | 3.3M | 4.8M | 5.8M | 3.6M | 3.7M | |
Capital Expenditures | 977.2K | 448K | 1.5M | 1.7M | 395K | 375.3K | |
Net Income | 4.2M | 2.4M | 2.3M | 3.2M | 5.2M | 5.4M | |
End Period Cash Flow | 10.5M | 11.9M | 8.2M | 7.4M | 16.1M | 16.9M | |
Change Receivables | (180.6K) | (4.1M) | (4.0M) | (3.1M) | (2.8M) | (2.6M) | |
Change To Netincome | 778.6K | 730K | 487K | 665K | 764.8K | 561.5K | |
Investments | (977.2K) | (448K) | (1.5M) | (1.7M) | (395K) | (414.8K) |
Electromed Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Electromed's current stock value. Our valuation model uses many indicators to compare Electromed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Electromed competition to find correlations between indicators driving Electromed's intrinsic value. More Info.Electromed is rated # 3 in return on equity category among its peers. It is rated # 2 in return on asset category among its peers reporting about 0.67 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Electromed is roughly 1.49 . At present, Electromed's Return On Equity is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Electromed by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Electromed Systematic Risk
Electromed's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Electromed volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Electromed correlated with the market. If Beta is less than 0 Electromed generally moves in the opposite direction as compared to the market. If Electromed Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Electromed is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Electromed is generally in the same direction as the market. If Beta > 1 Electromed moves generally in the same direction as, but more than the movement of the benchmark.
Electromed Thematic Clasifications
Electromed is part of Medical Equipment investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Medical Equipment industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
Medical Equipment | View |
Today, most investors in Electromed Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Electromed's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Electromed growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Electromed November 22, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Electromed help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Electromed. We use our internally-developed statistical techniques to arrive at the intrinsic value of Electromed based on widely used predictive technical indicators. In general, we focus on analyzing Electromed Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Electromed's daily price indicators and compare them against related drivers.
Downside Deviation | 2.95 | |||
Information Ratio | 0.2796 | |||
Maximum Drawdown | 13.47 | |||
Value At Risk | (4.47) | |||
Potential Upside | 6.65 |
Complementary Tools for Electromed Stock analysis
When running Electromed's price analysis, check to measure Electromed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Electromed is operating at the current time. Most of Electromed's value examination focuses on studying past and present price action to predict the probability of Electromed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Electromed's price. Additionally, you may evaluate how the addition of Electromed to your portfolios can decrease your overall portfolio volatility.
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |